This Article  • Full text  • PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citing articles on HighWire  • Citing articles on ISI (8)  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Topic Collections  • Photosensitivity Disorders  • Alert me on articles by topic

	Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings.

Chronic actinic dermatitis (CAD) is a persistent eczematous photodermatosis that usually affects elderly people.¹ Numerous therapeutic approaches have been tried for CAD; however, only psoralen–UV-A (PUVA) desensitization, cyclosporine, azathioprine, and/or a combination of them have consistently been successful.^2-4 Mycophenolate mofetil is an immunosuppressant that has been used primarily to prevent rejection in patients who have undergone renal transplantation.⁵ Because of its similar efficacy and safer profile, mycophenolate has been used as an attractive alternative to azathioprine in the treatment of immunologically mediated diseases.⁶ We describe 2 patients with CAD who successfully responded to PUVA desensitization using mycophenolate and low-dose prednisone treatment.

Report of Cases

Case 1

An 81-year-old white man presented with a 5-year history of a photosensitive eczematous eruption. This eruption had been present year round, with significant worsening in the summer despite the use of broad-spectrum sunscreens; it had also been treated with topical steroids, several courses of systemic steroids, and PUVA desensitization . . . [Full Text of this Article]

Case 2

Method

Results

Comment

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Mycophenolate mofetil and skin diseases
Hartmann and Enk
Lupus 2005;14:s58-s63.
ABSTRACT  

Mycophenolate mofetil and skin diseases
Hartmann and Enk
Lupus 2005;14:s58-s63.
ABSTRACT